Kornimate/medical-research-clean huggingface dataset:
relationship between bmi, physical fitness and motor skills in children with down's syndrome

Conditions: Down Syndrome

Summary: down syndrome is a congenital condition which includes physical mental, and functional abnormalities. it arises from defect involving chromosome 21, usually an extra copy (trisomy 21). purpose of this study will determine the relationship between bmi, physical fitness and motor skills in youth with down syndrome

this will be a cross-sectional study. the sample size is 169. the inclusion criteria will be diagnosed with trisomy 21, aged 6-11 years, abel to follow a minimum of two-step instructions, the minimum motor ability of participants with ds is independent locomotion where as the exclusion criteria will be medical condition that is contraindicated to moderate to vigorous physical activity such as cardiovascular problems, orthopedic instability, including those associated with ds (e.g., atlanto-axial instability), behavioral issues that hindered instruction. the bmi will be assessed using a person's height and weight. the formula is bmi = kg/m 2 where kg is a person's weight in kilograms and m 2 is their height in meters squared. physical fitness by using samu disability fitness battery (samu-disfit). the timed up and go test (tug), the deep trunk flexibility test (dtf), the hand grip test (hg), the timed stand test (tst), the 30-s sit-up (sup), the 6-min walk test (6mwt) and motor skills using test of gross motor development (tug-2) data will be analyzed using spss 22.0. frequency tables and bar charts will be used for descriptive statistics chi-square will be used to find the association

Eligibility criteria:
inclusion criteria: * diagnosed with trisomy 21. * aged 5-15 years. * abel to follow a minimum of two-step instructions. * the minimum motor ability of participants with ds is independent locomotion. exclusion criteria: * medical condition that is contraindicated to moderate to vigorous physical activity such as cardiovascular problems. * orthopedic instability, including those associated with ds (e.g., atlanto-axial instability). * behavioral issues that hindered instruction

Keywords: bmi down syndrome motor skills physical fitness test of gross motor development (tgmd-2) samu disability fitness battery (samu-disfit)
evaluation of a multiple behaviour programme for diarrhoea management

Conditions: Diarrhoeal Disease

Summary: control of diarrhoeal disease requires a comprehensive package of preventive and curative interventions. in zambia, the programme for awareness and elimination of diarrhoea (paed) aims to reduce child deaths by combating diarrhoea in lusaka province, zambia. the behaviour change component of the paed programme seeks to change behaviours important for diarrhoea prevention (handwashing with soap and exclusive breastfeeding) and improved treatment outcomes (use of oral rehydration solution (ors) and zinc in home management of child diarrhoea). the study aims to evaluate the feasibility of implementing a multiple behaviour change community programme to tackle diarrhoeal disease in children under-five and to assess the impact of this programme on practice of the target behaviours by caregivers of children under-five. the research questions will be answered through a a two-arm cluster-randomised trial (eight clusters per study arm).

specific objectives of the study are as follows: * evaluate the effect of the programme on ors and zinc uptake and usage, exclusive breastfeeding and handwashing with soap (primary objective) * determine the extent to which the programme has positively influenced key mediating factors that determine behaviour (i.e. social norms, physical infrastructure, attitudes, and disease and treatment perceptions) * investigate which components of the community programme (i.e. specific activities in clinics, community events etc.) are linked to the success of the programme (most acceptable, feasible etc) and in what context o validate model of intervention theory that explains how the context and mechanisms of the intervention interact to produce behavioural outcomes * determine which target populations are more likely to uptake the desired behaviours and identify the supporting factors that might explain this * conduct process evaluation to assess i) if the programme has been implemented as intended, ii) if the desired levels of reach and coverage have been achieved, iii) costs of implementation, iv) the extent to which changes in behaviour are likely to be due to the intervention.

Eligibility criteria:
inclusion criteria: * caregiver with child under six months (for assessment of handwashing and exclusive breastfeeding outcomes - healthy volunteers) * caregiver with child under five years with current or recent (last 7 days) diarrhoea (for assessment of ors and zinc outcomes) exclusion criteria: * not resident in study area

Keywords: behaviour change diarrhoeal disease handwashing breastfeeding diarrhoea management
precision medicine in cardiovascular surgery associated acute kidney injury

Conditions: Acute Kidney Injury; Surgery-Complications; Frailty

Summary: the goal of this prospective observational study is to define a risk profile for cardiovascular surgery associated acute kidney injury (aki), using clinical patient characteristics, operation parameters as well as blood and urine laboratory values. the main question it aims to answer is: • does a combination of the factors mentioned above better predict patient outcome than classical factors used to date in clinical practice? participants of this study are adults aged 18 and above who are scheduled for elective heart or main artery surgery, and who have given written informed consent.

the difficulty of precisely predicting aki following major surgery is a clinical challenge and unmet need as treatment should be introduced within 24-48 hours. in addition there is no available treatment to date apart from supportive therapy such as renal replacement therapy. therefore, early identification of patient-specific biomarkers and other clinical predictors could help to better understand the association with aki and other patient outcomes. in addition to the "classical" risk factors (age, diabetes, pre-existing ckd), frailty might represent another important variable, as shown in previous observational studies. importantly frailty is not unique to age, although it occurs in approximately 25% of those over 65 and affects more than half of the population aged 85 and older, as it has been shown to be highly prevalent in hospitalized patients and/or patients with ckd. furthermore, in preclinical studies the serum protein fetuin-a was identified as potential biomarker for vascular surgery associated aki. peak is a single center, prospective observational study involving several clinics at the university hospital bern. besides from demographic data and perioperative parameters, blood and urine are collected with high granularity during and immediately after surgery (15min after the first cut, start and end of cardiopulmonary bypass (cbp) or aortic clamping (x-clamp), 4 hours after surgery) and at day 1, 2, 3, and 7 (or discharge) post-surgery. in addition renal function will be assessed at day 90. furthermore, study participants will answer the edmonton frailty questionnaire at baseline and at day 90.

Eligibility criteria:
inclusion criteria: * patients undergoing elective cardiovascular surgery, such as valvular replacement surgery, with or without combined coronary artery bypass graft (cabg), or thoracic or abdominal aortic surgery. * written informed consent obtained prior to surgery. exclusion criteria: * patients with a kidney transplant or on renal replacement therapy * severe liver failure, defined by the presence of encephalopathy, factor v \ 1.5 on preoperative blood sample (within 4 weeks).

Keywords: kidney renal cardiac thoracic abdominal valvular replacement cabg aneurysm cardiopulmonary bypass ischemia
a phase 1/2a study of vs-7375 in patients with kras g12d-mutated solid tumors

Conditions: Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer; Colorectal Cancer; Solid Tumor, Adult; G12D Mutated KRAS

Summary: this study will assess the safety and efficacy of vs-7375 alone and in combination in patients with advanced solid tumors harboring a kras g12d-mutation.


Eligibility criteria:
key inclusion criteria: * individuals ≥18 years of age. * agreement to sign and date an informed consent form (icf) approved by the institutional review board (irb)/independent ethics committee (iec). * histologic or cytologic evidence of locally advanced unresectable or metastatic solid tumor harboring a kras g12d mutation. * must have received ≥1 prior line of standard systemic therapy for advanced or metastatic disease or experienced cancer progression within 6 months of neoadjuvant or adjuvant therapy. * measurable disease according to response evaluation criteria in solid tumors (recist) v1.1. * eastern cooperative oncology group (ecog) performance status 0 or 1 * adequate organ function * adequate cardiac function * recovered from all aes due to previous therapies to grade ≤1 or baseline. * agreement to use highly effective contraception key exclusion criteria: * underwent major surgical procedure as defined by the investigator, other than for diagnosis, within 4 weeks prior to cycle 1 day 1, * receipt of chemotherapy, targeted therapy, or radiotherapy (excluding palliative radiation) within 4 weeks or 5 half-lives, whichever is shorter, or immunotherapy within 4 weeks prior to cycle 1 day 1 * treatment with any investigational drug at least 4 weeks or 5 half-lives, whichever is shorter, prior to cycle 1 day 1. * history of treatment with direct and specific kras g12d inhibitors. * symptomatic, untreated, or actively progressing known central nervous system (cns) metastases. * inability to swallow oral medications. * evidence or history of uncontrolled, clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, coagulation, neurologic, dermatologic, autoimmune, or allergic disease * individuals who are pregnant or breastfeeding.

Keywords: kras g12d mutation solid tumors non small cell lung cancer lung cancer colorectal cancer metastatic cancer pancreatic cancer pancreatic ductal adenocarcinoma nsclc crc pdac pancreatic neoplasms colorectal neoplasms lung neoplasms gastrointestinal neoplasms kras ras
effects of measurement of handgrip strength on physical activity level for patients with diabetes type 2

Conditions: Diabetes Mellitus, Type 2; Physical Activity; Muscular Weakness

Summary: background: it is recommended that patients with diabetes type 2 keep themselves physically active and it is known that good muscular strength has a positive effect on these patients. aim: to determine whether physical activity level increases and whether other risk factors for cardiovascular disease are positively affected by including measurement of handgrip strength as part of the regular care program for patients with diabetes type 2 in primary care. method: patients with diabetes type 2 who go to regular check-ups by participating diabetes-nurses in primary care are randomized to either intervention or control group. in the intervention group, handgrip strength is measured in addition to standard care. the control group receives standard care at inclusion. handgrip strength is measured in both groups at 1 year follow-up. physical activity level is measured in both groups at inclusion and 1 year follow-up with a questionnaire. measurement of other risk factors for cardiovascular morbidity are measured at both inclusion and follow-up in both groups as dictated by standard care routines. expected results: measurement of handgrip strength can give health care personnel greater possibilities to identify those patients with diabetes type 2 who need to increase their activity level and to give them more concrete support. it is possible that the attention given to handgrip strength and physical activity may motivate patients to increase their activity level, become stronger and eventually reduce other risk factors for cardiovascular morbidity.


Eligibility criteria:
inclusion criteria: * patients with diabetes type 2 who go to regular check-ups with participating diabetes-nurses at primary health care centres in region västra götaland, sweden. exclusion criteria: * no gender, age or language restrictions.
serum folic acid status, genotyping mthfr 677c-->t, plasma homocysteine, dna methylation of igf2 gene and microbiota of the children: mother-children cohort study

Conditions: Folic Acid Deficiency

Summary: this study is part of the east jakarta cohort study to assess the current micronutrient status of the mothers and their children. the study also includes the assessment of genotyping of mthfr 677c--\>t of the mother and dna methylation of igf2 gene of the children.

the initial study recruited 315 mothers in the public health centre and one district hospital in east jakarta. the follow-up study is able to re-visit the 127 of them. this also includes 127 peers of the subject that lives in the same neighbourhood. the design of the study is case-cohort design, part study of the existing cohort. the assessment of the follow-up study includes the mother and the children born in the initial study. anthropometric measurement, socioeconomic data from a structured questionnaire, biomarker assessment, blood pressure were obtained from the subjects.

Eligibility criteria:
inclusion criteria: * participant in the previous study * apparently healthy * data complete * voluntarily to participate exclusion criteria: * not complete data * migrate * refuse to participate in the study

Keywords: serum folic acid genotyping dna methylation of igf2 east jakarta cohort study mother-children
a study to evaluate the safety, pharmacokinetics, and activity of ro7496353 in combination with a checkpoint inhibitor with or without standard-of-care chemotherapy in participants with locally advanced or metastatic solid tumors

Conditions: Metastatic Solid Tumor; Non-small Cell Lung Cancer; Gastric Cancer; Pancreatic Ductal Adenocarcinoma

Summary: the purpose of this study is to evaluate the safety and tolerability of ro7496353 when administered in combination with a checkpoint inhibitor (cpi) with or without standard-of-care (soc) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (nsclc), gastric cancer (gc) and pancreatic ductal adenocarcinoma (pdac). the study will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 or 1 * life expectancy at least 3 months * adequate hematologic and end organ function * histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy * measurable disease according to recist v1.1 on computed tomography (ct) or magnetic resonance imaging (mri) images within 28 days prior to enrollment * availability of representative tumor specimens in formalin-fixed, paraffin-embedded (ffpe) blocks or at least 15 unstained slides exclusion criteria: * pregnant or breastfeeding, or intending to become pregnant during the study or within 9 months after the final dose of oxaliplatin and within 6 months after the final dose of all other study treatment * any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and/or radiotherapy, within 3 weeks prior to initiation of study treatment * symptomatic, untreated, or actively progressing central nervous system (cns) metastases * significant cardiovascular disease (such as new york heart association class ii or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina * history of leptomeningeal disease * uncontrolled tumor-related pain * positive test for human immunodeficiency virus (hiv) infection * positive hepatitis b surface antigen (hbsag) test, and/or positive total hepatitis b core antibody (hbcab) test at screening * positive hepatitis c virus (hcv) antibody test at screening * known allergy or hypersensitivity to any component of the ro7496353 formulation or any of the study drugs or their excipients other protocol-defined inclusion/exclusion criteria may apply.
whole body vibration and bosu ball in spastic cerebral palsy

Conditions: Spastic Cerebral Palsy

Summary: cerebral palsy is a non-progressive neurodevelopmental disorder, also known as littles disease. the most common cause of physical and mental disabilities in the pediatric population. cerebral means brain and palsy means weakness or problems in muscles. spastic cerebral palsy is the common type of cerebral palsy characterized by spasticity or high muscle tone, results in stiffness etc. this will be a randomized clinical trial, data will be collected from sehat medical complex lahore. study will be conducted on 30 patients. inclusion criteria of this study is spastic diplegic cp children with age between 6 to 12 years, with gmfcs level 1 and 2 and those both male nd female, able to understand command will be included. those diplegic spastic cp who have orthopedic intervention/surgery, botulinum toxin injection within past six months, or medical problems such as pneumonia that prevented children from participating in exercises will be excluded.

group a: whole body vibration therapy group this group will be provided with whole body vibration therapy in spastic cerebral palsy children. exercise will be conducted 3 times a week for 8 weeks. pre and post session functional mobility and balance will be measured by pediatric balance scale and time up and go test. along routine physical therapy such as stretching exercise of achilles tendon, hamstring muscles, hip flexors and adductors, shoulder internal rotators, and wrist flexors, pronators, and ulnar deviator etc. group b: bosu ball training group this group will be provided with both sides up ball bosu training in spastic cerebral palsy children. exercise will be conducted 3 times a week for 8 weeks. pre and post session functional mobility and balance will be measured by pediatric balance scale and time up and go test. along routine physical therapy such as stretching exercise of achilles tendon, hamstring muscles, hip flexors and adductors, shoulder internal rotators, and wrist flexors, pronators, and ulnar deviator etc.

Eligibility criteria:
inclusion criteria: * spastic diplegic cp with gmfcs level i-ii * age 6-12 years * both male and female. * able to understand command exclusion criteria: * orthopedic surgery within 6 months * botulinum injection * parents refuse to participate * other diseases as pneumonia

Keywords: cerebral palsy wbvt bosu ball functional mobility balance
a study of atezolizumab plus carboplatin and etoposide with or without tiragolumab in patients with untreated extensive-stage small cell lung cancer

Conditions: Small Cell Lung Cancer

Summary: this study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (ce) compared with placebo plus atezolizumab and ce in participants with chemotherapy-naive extensive-stage small cell lung cancer (es-sclc). eligible participants will be stratified by eastern cooperative oncology group (ecog) performance status (0 vs. 1), ldh (\ uln), and presence or history of brain metastasis (yes vs. no) and randomly assigned in a 1:1 ratio to receive one of the following treatment regimens during induction phase: * arm a: tiragolumab plus atezolizumab plus ce * arm b: placebo plus atezolizumab plus ce following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (arm a) or atezolizumab plus placebo (arm b).


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed extensive-stage small cell lung cancer (es-sclc) * no prior systemic treatment for es-sclc * eastern cooperative oncology group (ecog) performance status of 0 or 1 * measurable disease, as defined by response evaluation criteria in solid tumors version 1.1 (recist v1.1) * adequate hematologic and end-organ function * treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage sclc exclusion criteria: * symptomatic or actively progressing central nervous system (cns) metastases * malignancies other than small cell lung cancer (sclc) within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome * active or history of autoimmune disease or immune deficiency * history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (ct) scan * positive test result for human immunodeficiency virus (hiv) * active hepatitis b or hepatitis c * severe infection at the time of randomization * treatment with any other investigational agent within 28 days prior to initiation of study treatment * prior treatment with cd137 agonists or immune checkpoint blockade therapies, anti-cytotoxic t lymphocyte-associated protein 4 (anti-ctla-4), anti-tigit, anti-pd-1, and anti-pd-l1 therapeutic antibodies * treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to randomization
implementation of prep care among women in family planning clinics

Conditions: PrEP Uptake; HIV; Prevention

Summary: this study will evaluate implementation strategies to address barriers and increase uptake of prep among black cisgender women in planned parenthood of illinois (ppil) health centers.


Eligibility criteria:
inclusion criteria: * eligible participants include ciswomen presenting at a ppil health center with a positive sti test (syphilis, gonorrhea, or chlamydia) and identified in the ehr using sti testing records and new fields for optimizing support of provider prep counseling. exclusion criteria: - participants will be excluded if they are not prep eligible, have a negative sti test, or are not identified in the ehr.